Physician profile
Robin E Wood
NPI 1043263130
$1,682.29
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $884 · 2022: $69.56 · 2023: $288 · 2024: $441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $729.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $728.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $904.97 | 2021-2022 | |
| Biotissue Holdings INC. | $186.65 | 2024 | |
| Hologic Sales and Service, LLC | $134.11 | 2024 | Novasure, Acessa Provu System |
| Abbvie INC. | $65.47 | 2023 | Liletta |
| Aspira Women'S Health INC | $55.66 | 2023-2024 | Ova1 |
| Astellas Pharma US INC | $55.65 | 2023 | Veozah |
| Sumitomo Pharma America, INC. | $49.48 | 2023 | Gemtesa |
| Myovant Sciences INC. | $41.13 | 2022 | |
| Mayne Pharma Commercial LLC | $37.20 | 2023 | |
| Coopersurgical, INC. | $36.43 | 2024 | Paragard T 380a |
| Pfizer INC. | $32.50 | 2023 | |
| Evofem Biosciences, INC. | $23.56 | 2023 | Phexxi |
| Biogen, INC. | $22.47 | 2024 | Zurzuvae |
| Millicent US INC | $21.47 | 2024 | Intrarosa |
| Meditrina | $8.21 | 2023 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $7.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Wood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.